madman
Super Moderator
Abstract
INTRODUCTION AND OBJECTIVES:
Phosphodiesterase Type 5 (PDE5) inhibitor is effective in treating erectile dysfunction and is generally safe concerning cardiovascular (CV) risk profiles. We analyzed risk ratios and outcome of major adverse cardiovascular to depending on different period of time the patient taking PDE5 inhibitor.METHODS:
Data from Global Collaborative Network with 155 healthcare organizations was retrieved. Men between 50-70 years old diagnosed with erectile dysfunction (ED) after the first day of 2015 without secondary pulmonary hypertension one year ago or coronary artery disease 5 years ago was included. Those started taking Tadalafil 2.5 mg or 5 mg daily since ED diagnosed was defined as Group Regular. Those who take PDE5 inhibitor (Sildenafil, Tadalafil 10 mg or 20 mg, Vardenafil, and Avanafil) on demand was defined as Group Demand. Outcomes were assessed from day 1 to day 1095 after the index event by Propensity score matching and Kaplan-Meier survival analysis.RESULTS:
After propensity score matching with age, comorbidities, renal function, and lipid profile, 72908 patients in each group were analyzed. Baseline age and major comorbidities were comparable. Of laboratory data, Group Regular has higher creatinine level, level, while lower LDL, triglyceride, and HbA1c. All-cause mortality was significantly lower in Group Regular than Group Demand, with reduced hazard ratios over median follow-ups of 2.3 and 3 years, respectively (Table 1).CONCLUSIONS:
Regular low-dose Tadalafil use after ED diagnosis significantly reduced 3-year all-cause mortality and MACE, suggesting cardiovascular benefits beyond erectile function.
